Skip to content

Erasca, Inc. ERAS Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.68B+1,106%
Enterprise value$4.68B+1,170%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s interest income (expense), nonoperating?
Erasca, Inc. (ERAS) reported interest income (expense), nonoperating of $4.45M in Q1 2026.
How has Erasca, Inc.'s interest income (expense), nonoperating changed year-over-year?
Erasca, Inc.'s interest income (expense), nonoperating decreased by 6.1% year-over-year, from $4.74M to $4.45M.
What is the long-term trend for Erasca, Inc.'s interest income (expense), nonoperating?
Over 4 years (2021 to 2025), Erasca, Inc.'s interest income (expense), nonoperating has grown at a 205.8% compound annual growth rate (CAGR), from $190K to $16.61M.